Targeting the Mammalian Target of Rapamycin Pathway in Osteosarcoma Using Combinative Chemotherapy.
Liu Pei-yi,Zhang Wei-bin,Wei Yi-yong
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20112107
IF: 6.133
2013-01-01
Chinese Medical Journal
Abstract:Osteosarcoma is the most common primary malignant bone sarcoma, and occurs predominantly in children and young adults. The overall survival of patients with osteosarcoma remains low at approximately 60%.1 The prognosis of osteosarcoma patients is highly associated with response to chemotherapy. Although multiple chemotherapy regimens have improved the outcome of patients with osteosarcoma, resistance to current regimens has been reported in more than 30% of patients,2 highlighting the need for novel, targeted therapies. The mammalian target of rapamycin (mTOR), also known as FK506 binding protein 12-rapamycin associated protein 1, is a serine/threonine protein kinase belonging to the phosphatidylinositol 3-kinase-related kinase (PI3K) protein family.3,4 mTOR is upregulated by a number of upstream factors, including insulin, growth factors and amino acids. The mTOR pathway is downregulated in certain human diseases, such as diabetes mellitus; and recent evidence has shown that this pathway is upregulated in certain cancers. mTOR is considered to be a key regulator of cell growth, proliferation, motility, survival, protein synthesis and transcription.5, 6 mTOR is a subunit of the mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2) molecular complexes. mTORC1 is composed of mTOR, regulatory associated protein of mTOR, mammalian LST8/G-protein β-subunit like protein, AKT1 substrate 1 (AKT1S1) and DEP domain containing MTOR-interacting protein. The activity of this complex is stimulated by insulin, growth factors, serum, phosphatidic acid, amino acids (particularly leucine), and oxidative stress. Conversely, mTORC1 is inhibited by low nutrient levels, growth factor deprivation, reductive stress, rapamycin, caffeine, farnesylthiosalicylic acid, curcumin and oleanolic acid (OA).3, 4, 7, 8 The mTORC2 complex is composed of mTOR, rapamycininsensitive companion of mTOR, GβL and mammalian stress-activated protein kinase interacting protein 1.9 mTORC2 has been shown to act as an important regulator of the cytoskeleton through its stimulation of F-actin stress fibers, paxillin, RhoA, Rac1, Cdc42 and protein kinase C α. Previous studies have shown that mTORC2 is regulated by insulin, growth factors, serum and in response to nutrient levels. mTORC2 has been identified as a rapamycin-insensitive entity, since acute exposure to rapamycin did not affect mTORC2 complex activity or Akt phosphorylation. However, subsequent studies showed that at least in some cell lines, mTORC2 is sensitive to chronic exposure to rapamycin. Rapamycin, also known as Sirolimus, functions by forming a complex with the cytosolic protein FK-binding protein 12, which subsequently inhibits the mTOR pathway by directly binding mTORC1. Rapamycin has potent immunosuppressive and anti-proliferative properties, and this latter ability may underlie its efficacy as an anti-cancer drug. Other mTOR inhibitors such as temsirolimus (CCI-779) and everolimus (RAD001) are currently being tested for use in treating cancers such as glioblastoma multiforme and mantle cell lymphoma. The newly identified OA is an mTOR signaling agent used for the treatment of osteosarcoma.7, 10 THE mTOR PATHWAY IN OSTEOSARCOMA Ewing sarcoma (ES) is one of the most common forms of osteosarcoma, and comprises Ewing sarcoma arising from the bone, and extraosseous Ewing sarcoma arising from soft tissues. Treatment of ES is successful in many cases, using a combination of surgery and chemotherapy. Several novel chemotherapy regimens have been recently reported, and there is significant interest in identifying molecular targets in ES, including components of the mTOR signal pathway. Previous studies have shown that low-dose rapamycin can inhibit tumor growth and angiogenesis in ES, without inhibiting the phosphorylation of p70s6k and AKT. Cyclooxygenase 2 (COX-2) levels are inhibited by low-dose treatment of ES with rapamycin, suggesting that the anti-angiogenic effect of rapamycin in ES may be mediated by suppression of COX-2.2 Because mTOR is a central regulator of translation and cell proliferation, previous studies focused on the potential role of mTOR in the development of ES. These studies showed that ES cells carrying Ewing sarcoma breakpoint region 1 (EWSR1)/Friend leukemia virus integration 1 (FLI-1) alleles, expressed total and phosphorylated mTOR protein. Furthermore, rapamycin blocked the proliferation of ES cell lines by promoting cell cycle arrest at the G1 phase, via downregulation of EWSR1/FLI-1.11,12 Studies employing the MG-63 human osteosarcoma cell line, revealed that treatment with rapamycin 4-6 hours after the addition of serum growth factors, still led to G1 phase arrest. This correlated with the inhibition of cyclindependent kinase (CDK) activity following the addition of rapamycin. These studies demonstrated that FK506 binding protein (FKBP)-rapamycin is capable of modulating the association of cyclin D1-CDK during early G1 phase in MG-63 human osteosarcoma cells. Taken together, these reports indicate that mTOR signaling plays a central role in ES and human osteosarcoma cells,13,14 and highlights the possibility that rapamycin may be used to complement existing chemotherapy regimens in osteosarcoma patients. A recent study showed that FK506, a rapamycin derivative used as a clinical immunosuppressant, stimulates osteoblastic differentiation, and also enhances BMP-4 induced osteoblastic differentiation in the rat osteosarcoma cell line.15 If immunosuppressants are capable of inducing osteoblastic differentiation in humans, these may represent useful compounds for bone tissue transplantation. These results also suggest that rapamycin and its derivatives may be used in differentiation therapy to cure osteosarcoma. RAPAMYCIN THERAPY IN ANIMAL OSTEOSARCOMA MODELS The mTOR pathway has been shown to contribute to the growth, progression and chemoresistance of several cancers. Novel compounds targeting this pathway may therefore be developed as potentially valuable therapeutic strategies. Optimal development of these compounds requires consideration of the regimen, dose and other aspects for their use in combination with other agents. Preliminary studies investigating the mechanisms underlying activation of the mTOR pathway and the anti-tumor effects of rapamycin should first be conducted in canine or murine osteosarcoma cells. Several investigators have used information from the Comparative Oncology Trials Consortium regarding relevant canine populations with osteosarcoma and murine models of osteosarcoma (K7M2), to inform the development of mTOR inhibitors for future use in osteosarcoma patients.16 In one study, the aim was to define a safe, pharmacokinetically relevant, and pharmacodynamically active dose of rapamycin in dogs with appendicular osteosarcoma. Dogs underwent a pre-treatment tumor biopsy and collection of baseline peripheral blood mononuclear cells (PBMCs), and subsequently received a single, intramuscular dose of rapamycin. Rapamycin may be safely administered to dogs, as they are capable of tolerating therapeutic exposures. In this study, modulation of the downstream target of mTOR, pS6RP/S6RP, in tumor tissue and PBMCs, was not dependent on dose.17 In a separate study, treatment of canine osteosarcoma with rapamycin led to a timedependent decrease in phosphorylated mTOR expression and a decrease in detectable levels of phosphorylated p70S6 kinase. These data indicated that mTOR and its downstream products are present and active in canine osteosarcoma cells.18 The mTOR pathway may be inhibited by rapamycin, and indeed, treatment of cells with rapamycin decreased the surviving tumor cell fraction. Taken together, these data support the molecular basis for further study into the use of mTOR inhibitors as anti-neoplastic drugs for use in dogs with osteosarcoma. Research from a murine model of osteosarcoma (K7M2) found that targeting the mTOR pathway with the rapamycin analog, CCI-779, significantly inhibited experimental lung metastasis in vivo.16 These results indicate that specific targeting of the mTOR pathway inhibits cancer growth and metastasis, and treatment with mTOR inhibitors before and after surgery may represent a novel therapeutic approach. USE OF RAPAMYCIN IN COMBINATION CHEMOTHERAPY TO TREAT OSTEOSARCOMA Several studies have shown that rapamycin inhibits the mTOR pathway, thus restricting both cancer growth and metastasis. Inhibition of cell growth is associated with an increase in G1 and a decrease in the S-phase of the cell cycle, concomitant with the downregulation of cyclin D1. Treatment with rapamycin also led to downregulation of the activity of p70S6, pAkt and p-mTOR, but had no effect on phosphorylated glycogen synthase kinase 3 beta (pGSK-3beta), p44Erk, phosphorylated cyclin dependant kinase 1 (CDK1), tuberous sclerosis 1/2 (TSC1/2) or heat shock protein 90 (Hsp90).19 Rather than depending on a single chemotherapy approach, combination chemotherapy combines rapamycin with other useful chemotherapy drugs, resulting in a higher disease-free survival rate and a lower rate of resistance. Ultimately, such treatment regimens will improve the therapeutic management of osteosarcoma. Studies have shown that rapamycin and its derivative, combined with zoledronate (ZOL), insulin-like growth factor-I receptor (IGF-IR) inhibitors and 17-AAG, are effective in treating osteosarcoma both in vivo and in vitro. In one study investigating the in vivo effects of RAD001, osteosarcoma cell proliferation was inhibited in a dose and time-dependent manner, with no modification in cellcycle distribution. Combination of RAD001 with ZOL augmented the inhibition of cancer cell proliferation, and led to a decrease in PI3K/mTOR signaling compared with either treatment alone. The drug combination reduced tumor development in two murine models of osteoblastic or osteolytic osteosarcoma. Furthermore, ZOL reversed RAD001 resistance in osteosarcoma, limiting osteosarcoma cell growth when combined with RAD001.20,21 Several studies have investigated the effect of rapamycin and its derivative, in combination with IGF-IR inhibitors, on osteosarcoma. IGF-IR is a cell surface receptor tyrosine kinase that mediates cell survival signaling and supports tumor progression in many human cancers, including sarcomas in children and young adults.22 As a consequence, targeting the IGF-IR has become a major focus for cancer drug development. A study of six osteosarcoma xenograft tumor models evaluated for growth inhibition after monotherapy with the IGF-IR inhibitor, R1507, rapamycin, and the combination of both drugs, found that R1507 led to a delay in tumor growth and improved event-free survival in four of six osteosarcoma xenograft tumor lines. R1507 negates increased signaling through AKT in response to mTOR inhibition, indicating that the combination is worthy of further evaluation in patients.23 Another study investigated the effect of BIIB4 and BIIB5 antibodies, which block both IGF-I and IGF-II binding to IGF-IR using competitive and allosteric mechanisms, respectively. Compared to treatment with either antibody alone, the combination of BIIB4 and BIIB5 significantly enhanced the anti-tumor activity of the epidermal growth factor receptor inhibitor, erlotinib, and the mTOR inhibitor, rapamycin.22 Rapamycin treatment does not markedly suppress vascular endothelial growth factor (VEGF) in tumors. One important study showed that CP751871, a human antibody that blocks IGF-IR ligand binding, caused complete IGF-IR downregulation, suppression of AKT phosphorylation and tumor-derived VEGF in sarcoma xenografts.6 These data suggest that blockade of IGF-IR suppresses tumor-derived VEGF to a level where rapamycin can effectively suppress the response in vascular endothelial cells. 17-AAG is an inducer of apoptosis, causing the effective depletion of glutathione and mitochondrial membrane depolarization, strong activation of caspase-8 and 9, and release of apoptosis inducing factors from the mitochondria to the cytosol. 17-AAG also downregulates pAkt, p44Erk, p-mTOR, p70S6, TSC1/2, pGSK-3beta and Hsp90. Thus Hsp90 inhibition may also merit further study in the therapy of osteosarcoma.17, 19 The maintenance of bone mass requires a balance between bone formation and bone resorption. In the tumoral bone environment, cancer cells disturb this balance by interacting with bone cells to create a favorable site for tumor growth and promote pathological bone changes. Nitrogen containing bisphosphonates (N-BP) were originally developed as antiresorptive agents; however researchers found that they also inhibit tumor cell proliferation and increase atypical apoptosis of bone tumor cells, regardless of the p53 and Retinoblastoma status. Rapamycin and its derivatives, as well as N-BP must be considered as multi-functional molecules, simultaneously affecting bone and tumor metabolism.8 These two compounds may be combined for use in the treatment of primary bone tumors and bone metastases. Previous studies have shown that rapamycin directly acts on ROS cells, and induces osteoblastic differentiation compared to treatment with FK506 and cyclosporin A. Treatment of ROS cells with rapamycin caused a significant increase in alkaline phosphatase (ALP) activity and in the expression of osteopontin and osteocalcin mRNA, compared to treatment with FK506, which induced a moderate increase in ALP activity and decreased expression of osteopontin. Cyclosporin A caused a decrease in ALP activity and in the expression of type 1 alpha 1 collagen mRNA. Rapamycin also significantly enhanced differentiation induced by 1,25(OH)2-VitaminD3.24 THE SIDE EFFECTS OF RAPAMYCIN TREATMENT The use of large doses of rapamycin and its long-term use may have an immunosuppressive effect in patients. As with all immunosuppressive medications, rapamycin may decrease the body's immunity. Rapamycin acts on mTORC2,17,18 and this disruption leads to diabetic-like symptoms including decreased glucose tolerance and insensitivity to insulin. Rapamycin also partially suppresses mTORC1 function, efficiently inhibiting S6 kinase 1 (S6K1) but not the eukaryotic translation initiation factor 4E (eIF4E), thus only partially blocking translation. Dual PI3K-mTOR inhibitors may be conceptually superior to catalytic mTOR inhibitors; however, this broad inhibition is toxic to normal cells.3 CONCLUSION Osteosarcoma is a highly aggressive tumor with a higher rate of metastasis than most cancers in children and young adults. The prognosis of patients with osteosarcoma is associated with response to chemotherapy; however osteosarcoma is highly resistant to current treatment regimens. Understanding the molecular mechanisms underlying the development and malignant behavior of osteosarcoma is crucial for developing targeted therapeutic approaches and for the identification of novel chemotherapy agents.